Rational Vaccines Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 20
Employees
  • Latest Deal Type
  • Later Stage VC
  • (In Progress)
  • Latest Deal Amount
  • $15M
Latest Deal Amount
  • Investors
  • 8

Rational Vaccines General Information

Description

Operator of an infectious disease company intended to combat all diseases resulting from herpes. The company has developed rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates, enabling physicians to help improve lives by reducing the suffering of those infected and reduce the spread of the virus.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 8 Cabot Road
  • Suite 3800
  • Woburn, MA 01801
  • United States
+1 (781) 000-0000

Rational Vaccines Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rational Vaccines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Mar-2020 $15M 000.00 In Progress Pre-Clinical Trials
4. Early Stage VC 27-Mar-2020 00.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 15-Feb-2019 000.00 000.00 Completed Pre-Clinical Trials
2. Seed Round 05-Sep-2017 $8.2M $8.94M 0000 Completed Pre-Clinical Trials
1. Seed Round 30-Sep-2015 $740K $740K 00.000 Completed Startup
To view Rational Vaccines’s complete valuation and funding history, request access »

Rational Vaccines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series A2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Seed-2 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed-1 4,140,214 $0.000010 $0.09 $1.09 $1.09 1x $1.09 12.86%
Seed 2,322,492 $0.000010 $0.02 $0.3 $0.3 1x $0.3 7.21%
To view Rational Vaccines’s complete cap table history, request access »

Rational Vaccines Executive Team (8)

Name Title Board Seat Contact Info
Agustin Fernandez III Co-Founder, Chief Executive Officer & Board Member
Aziz Friedrich Chief Financial Officer & Vice President, Operations
David Brindley Ph.D Chief Regulatory and IP Officer & Chief Operating Officer
Edward Gershburg Ph.D Chief Technology Officer
Luis Rios-Nogales Ph.D Chief Development and Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Rational Vaccines Board Members (7)

Name Representing Role Since
Agustin Fernandez III Rational Vaccines Co-Founder, Chief Executive Officer & Board Member 000 0000
Diane Abbitt Self Board Member 000 0000
Jason Camm Thiel Capital Board Member 000 0000
Jeffrey Madden Self Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

Rational Vaccines Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rational Vaccines Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arab Angel Venture Capital Minority 000 0000 000000 0
Flight Ventures Venture Capital Minority 000 0000 000000 0
Abstract Ventures Venture Capital Minority 000 0000 000000 0
Founders Fund Venture Capital Minority 000 0000 000000 0
Ironbridge Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »